Skip to content

Alfuzosin

alpha-Adrenergic Blocker — GENITO URINARY SYSTEM AND SEX HORMONES

Also known as: alfuzosin HCl, alfuzosin hydrochloride, SL 77, xatral

OfpFDA approvedATC G04CA01ATC G04CA51

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Alfuzosin is an ofp drug in the alpha-Adrenergic Blocker class catalogued in DrugCentral. It was first approved by the FDA in 2003. Its mechanism of action is classified as Adrenergic alpha-Antagonists. DrugCentral lists 7 molecular targets, including ADRA1B, Adra1d and ADRA1D. Recorded indications include Benign prostatic hyperplasia.

  • Approval status: ofp (first approved 2003 by the FDA).
  • Drug class: alpha-Adrenergic Blocker.
  • Mechanism of action: Adrenergic alpha-Antagonists.
  • Molecular targets: ADRA1B, Adra1d, ADRA1D and ADRA1A (7 listed in DrugCentral).
  • Indications: Benign prostatic hyperplasia.
  • ATC code: G04CA01 (Alpha-adrenoreceptor antagonists).
  • Molecular formula: C19H27N5O4; molecular weight 389.46 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Benign prostatic hyperplasia

Contraindications (13)

  • Acute nephropathy
  • Angina pectoris
  • Cataract surgery
  • Congenital long QT syndrome
  • Disease of liver
  • Hepatic failure
  • Intraoperative floppy iris syndrome
  • Low blood pressure
  • Micturition syncope
  • Orthostatic hypotension
  • Progressive Angina Pectoris
  • Prolonged QT interval
  • Torsades de pointes

Mechanism & targets

Mechanism of action (MoA)Adrenergic alpha-Antagonists
Established pharmacologic classalpha-Adrenergic Blocker

Molecular targets (7)

TargetGeneActionActivity
Alpha-1B adrenergic receptorADRA1BantagonistKi 8.55
Alpha-1D adrenergic receptorAdra1dunknownKi 8.46
Alpha-1D adrenergic receptorADRA1DantagonistKi 8.44
Alpha-1A adrenergic receptorADRA1AantagonistKi 8.09
AcetylcholinesteraseACHEunknownIC50 7.75
Alpha-1A adrenergic receptorADRA1AunknownKi 7.64
Solute carrier family 22 member 1SLC22A1unknownIC50 4.83

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
2003-06-12FDA—COVIS PHARMA SARL

ATC classification

ATC codeTherapeutic hierarchy
G04CA01GENITO URINARY SYSTEM AND SEX HORMONES › UROLOGICALS › DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY › Alpha-adrenoreceptor antagonists
G04CA51GENITO URINARY SYSTEM AND SEX HORMONES › UROLOGICALS › DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY › Alpha-adrenoreceptor antagonists

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Acute kidney injury363.1
Drug interaction243.0
Drug dispensed to wrong patient194.5
Hypotension189.0
Syncope176.9
Cholestasis162.5
Orthostatic hypotension154.5
Agranulocytosis145.1
Antimicrobial susceptibility test resistant132.7
Minimum inhibitory concentration128.8
Wrong patient received product115.8
Fall112.7

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Alfuzosin is on its molecule page.

Molecular formulaC19H27N5O4
Molecular weight389.46 g/mol
CAS number81403-80-7
InChIKeyWNMJYKCGWZFFKR-UHFFFAOYSA-N
PubChem CID2092
COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N(C)CCCNC(=O)C1CCCO1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Alfuzosin used for?

DrugCentral lists the following indications for Alfuzosin: Benign prostatic hyperplasia.

How does Alfuzosin work?

Alfuzosin is classified as Adrenergic alpha-Antagonists; its molecular targets in DrugCentral include ADRA1B (antagonist), Adra1d, ADRA1D (antagonist) and ADRA1A (antagonist).

When was Alfuzosin first approved?

Alfuzosin was first approved by the FDA in 2003.

What drug class does Alfuzosin belong to?

Alfuzosin is in the alpha-Adrenergic Blocker class.

What is the chemical formula of Alfuzosin?

Alfuzosin has the molecular formula C19H27N5O4 and a molecular weight of 389.46 g/mol.

Browse: all drugs starting with A · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFP
First approval2003-06-12
AgencyFDA
Targets7
Indications1
FormulaC19H27N5O4
DrugCentral ID115
Interactive profile